Introduction
============

Percutaneous biopsy of intrapelvic lesions is difficult because various organs (e.g., small and large bowels, bladder and ureters, and uterus and ovaries) or large vessels usually surround the target lesion. Accordingly, risks of major organ injury or bleeding are associated with percutaneous biopsy. Therefore, for intrapelvic lesions, positron emission tomography/computed tomography (PET/CT) may be useful as the next step of computed tomography (CT) or magnetic resonance imaging (MRI) \[[@b1-usg-18028],[@b2-usg-18028]\]. However, these imaging modalities are expensive and sometimes inaccurate, because some benign conditions mimic malignancy \[[@b3-usg-18028]\]. This may lead to the need for surgical confirmation as part of the planned management of a case when percutaneous biopsy is unavailable in practice.

Previous studies have suggested that transrectal ultrasound (TRUS) or transvaginal ultrasound (TVUS)-guided biopsy is useful and safe for sampling intrapelvic lesions \[[@b4-usg-18028]-[@b9-usg-18028]\]. According to the literature, the rate of diagnostic biopsies (i.e., those that enable a histologic diagnosis) is roughly 85%-95%. The proximity between the TRUS or TVUS probe and deeply located intrapelvic lesions improves the sonic window and shortens the biopsy distance, which may result in a good diagnostic yield of those approaches \[[@b4-usg-18028],[@b10-usg-18028],[@b11-usg-18028]\]. However, the data showing the usefulness of TRUS- and TVUS-guided biopsy are still insufficient, and it is also unclear whether TRUS- or TVUS-guided biopsy is useful in oncologic patients.

Thus, we externally validated the diagnostic usefulness of TRUS-or TVUS-guided biopsy for pelvic masses when performed by an experienced radiologist. We then also analyzed the diagnostic performance of these biopsy techniques in patients with an underlying malignancy.

Materials and Methods
=====================

Patients
--------

This retrospective study was performed in accordance with the Declaration of Helsinki and approved by our Institutional Review Board. The requirement for informed consent was waved. We retrospectively reviewed a consecutive series of 30 patients (median age, 60.5 years) who underwent TRUS-guided (n=19) or TVUS-guided (n=11) biopsy for a pelvic mass between May 2014 and December 2017 at a single institution. All the patients had prebiopsy CT or MRI to demonstrate the target lesion for biopsy. The mean interval between the prebiopsy CT/MRI and biopsy was 8.5 days (range, 1 to 61 days).

Of the 30 patients, 20 (66.7%) had an underlying malignancy (i.e., oncologic patients), belonging to the following categories: gynecologic cancer (e.g., uterine, cervical, endometrial, or vaginal cancers) (n=7), colorectal cancer (n=5), prostate cancer (n=5), bladder cancer (n=1), melanoma (n=1), and nasopharyngeal cancer (n=1). In this study, oncologic patients who underwent biopsy were defined as those who had a histologically proven primary cancer and underwent biopsy for a recurrent or metastatic lesion.

TRUS- or TVUS-Guided Biopsy
---------------------------

An experienced radiologist (S.Y.P.; 6 years' experience with TRUS-and TVUS-guided biopsy) performed the biopsy. Local anesthesia with 10 mL of 1% lidocaine via a 21-gauge 15-cm Chiba needle (Cook Medical, Bloomington, IN, USA) was administered to the rectal or vaginal mucosa. The biopsy was performed using an 18-gauge 20-cm biopsy gun (ACECUT, TSK Laboratory, Tochigi, Japan) under US guidance (Aixplorer US system, SuperSonic Imagine, Aix-en-Provence, France). The left lateral decubitus position was used for the TRUS approach and the lithotomy position was applied for the TVUS approach. Prophylactic antibiotics (e.g., second or third-generation cephalosporin, or fluoroquinolone) were administered intravenously before biopsy and orally after biopsy for 7 days because the biopsy routes, which involved the rectal or vaginal canal, were not completely aseptic. In addition, a prebiopsy enema with glycerin solution was conducted 1-2 hours before TRUS-guided biopsy. All patients were discharged 4-6 hours after the biopsy to monitor immediate complications. No patients were hospitalized for the biopsy.

Radiologic, Pathologic, and Clinical Data Analyses
--------------------------------------------------

All CT, MRI, and ultrasonography (US) images were archived using a picture archiving and communication system (PathSpeed, GE Healthcare, Milwaukee, WI, USA) for the analysis. Two radiologists (S.Y.P. and S.Y.W.) evaluated the pelvic lesions in consensus with prebiopsy CT or MRI as follows: (1) lesion size, (2) lesion nature (e.g., solid or cystic), and (3) lesion location (e.g., perirectal space, uterus or ovary, vaginal vault, pelvic sidewall, or bladder). A lesion was considered to have a cystic nature when its non-enhancing cystic or necrotic portions comprised over half of the lesion. On the basis of US images and reports, the biopsy core number and biopsy distance were assessed. The biopsy distance was defined by the mean length of the biopsy needle seen on US images.

The final pathologic report of the biopsy specimens from an experienced pathologist (H.S.K.; 4 years' experience) was our reference standard to determine whether the biopsy result was diagnostic or non-diagnostic, and whether the lesion was malignant or benign. We compared the radiologic impressions obtained through CT or MRI and the findings of the prebiopsy US examination with the pathologic result of the biopsy specimen.

Major complications were investigated based on the patients' medical records. Major complications were defined as those with a Clavien-Dindo classification of 2 or greater (i.e., complications requiring pharmacologic, interventional, or surgical treatment) \[[@b12-usg-18028]\].

Statistical Analysis
--------------------

We calculated the rate of diagnostic biopsies. For patients with diagnostic results, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of TRUS- or TVUS-guided biopsy in diagnosing the malignancy were assessed. These measures of diagnostic performance were also analyzed in patients with an underlying malignancy.

Results
=======

Radiologic and Biopsy-Related Characteristics
---------------------------------------------

For the 30 pelvic lesions in 30 patients, the median lesion size was 4.5 cm (range, 0.9 to 13.0 cm). The lesions had a solid nature in 25 patients and a cystic nature in 5. The most common location of the biopsied lesions was the perirectal space (n=10), followed by gynecologic organs ([Table 1](#t1-usg-18028){ref-type="table"}). Of the 30 patients, 20 (66.7%) had an underlying malignancy. The median number of biopsy cores was 4 (range, 2 to 7). The median biopsy distance was 2.4 cm (range, 1.4 to 5.6 cm).

Biopsy Performance and Major Complications
------------------------------------------

The overall diagnostic rate of TRUS- or TVUS-guided biopsy was 93.3% (28 of 30). The diagnostic biopsies revealed 17 malignant and 11 benign lesions. The biopsy-proven malignant lesions consisted of recurrent gynecologic cancer (n=4) ([Fig. 1](#f1-usg-18028){ref-type="fig"}), recurrent prostate cancer (n=4), recurrent colorectal cancer (n=3) ([Fig. 2](#f2-usg-18028){ref-type="fig"}), lymphoma (n=2), recurrent bladder cancer (n=1), recurrent nasopharyngeal cancer (n=1), recurrent melanoma (n=1), and primary ovarian cancer before neoadjuvant chemotherapy (n=1). The biopsy-proven benign lesions consisted of inflammation (n=6), uterine leiomyoma (n=2), ganglioneuroma (n=1), lymphangioma (n=1), and retroperitoneal fibrosis (n=1).

For the diagnostic biopsies, the sensitivity, specificity, PPV, NPV, and accuracy of overall TRUS- or TVUS-guided biopsy for identifying malignancy were 100% (17 of 17), 72.7% (8 of 11), 85.0% (17 of 20), 100% (8 of 8), and 89.3% (25 of 28), respectively ([Table 2](#t2-usg-18028){ref-type="table"}). No patient had major complications requiring pharmacologic, interventional, or surgical treatment.

The diagnostic rates of TRUS and TVUS were 94.4% (17 of 18) and 90.0% (9 of 10), respectively. The sensitivity, specificity, PPV, NPV, and accuracy of TRUS-guided biopsy were all 100% for diagnosing malignancy, while the corresponding values of TVUS-guided biopsy were 100% (4 of 4), 50.0% (3 of 6), 57.1% (4 of 7), 100% (3 of 3), and 70.0% (7 of 10), respectively.

For the 20 oncologic patients, the overall diagnostic biopsy rate was 95.0% (19 of 20). For the diagnostic biopsies, the sensitivity, specificity, PPV, NPV, and accuracy were 100% (14 of 14), 60.0% (3 of 5), 87.5% (14 of 16), 100% (3 of 3), and 89.5% (17 of 19), respectively, for diagnosing malignancy.

Non-diagnostic Cases
--------------------

In this study, two patients had non-diagnostic results. One patient (age, 86 years old; female) had a uterine mass, measuring 10.5 cm in size ([Fig. 3](#f3-usg-18028){ref-type="fig"}). On contrast-enhanced CT, the lesion had large intratumoral cystic or necrotic portions without enhancement (i.e., it was cystic in nature). TVUS-guided biopsy with seven cores was performed under the impression of primary uterine sarcoma, and the pathologic result was non-diagnostic because the biopsied specimens had only necrotic tissues surrounded by fibrous connective tissue without cancer cells. This patient was lost to follow-up after the biopsy. The other patient (age, 74 years old; male) had a focal solid mass, measuring 3.6 cm, near the pelvic sidewall. TRUS-guided biopsy with 5 cores was performed under the impression of recurrent prostate cancer. The pathologic examination indicated that the biopsy was non-diagnostic because only nonspecific muscle was found. The lesion had increased in size on follow-up CT taken 1 year later and radiation therapy was performed on the basis of the radiologic findings.

Discussion
==========

In this study, we analyzed the diagnostic performance and safety of TRUS- or TVUS-guided biopsy for pelvic masses. The diagnostic rate (i.e., the proportion of biopsies that allowed a specific pathologic diagnosis) was greater than 90% for all patients and for oncologic patients, while there were no major complications requiring treatment. In addition, these biopsy techniques seemed to be highly sensitive for identifying malignancy, as shown by the sensitivity of 100% for all patients and for oncologic patients. Therefore, in oncologic patients, TRUS- or TVUS-guided biopsy may be very useful for safely and accurately identifying cases of pelvic metastasis or recurrence.

The sonic window is generally poor when the distance between the US probe and targeted region increases. In addition, acoustic shadowing from the bowels in the pelvic cavity often makes the target lesion invisible. Thus, visualizing deep pelvic masses using transabdominal US is more difficult than visualizing superficially located lesions \[[@b10-usg-18028]\]. However, the distance between deep pelvic masses and the TRUS or TVUS probe is short because the proximal vagina or rectum is usually located in the central portion of the pelvic cavity \[[@b4-usg-18028],[@b11-usg-18028]\]. In this study, the median biopsy distance was 2.4 cm, which may allow a good sonic window, subsequently resulting in accurate and safe tissue sampling, with the concomitant avoidance of adjacent organ injury.

In oncologic patients, the accurate diagnosis of recurrent disease is crucial before treatment planning. In daily practice, CT and MRI are important imaging modalities for initially detecting pelvic recurrence. However, the radiologic features of recurrent disease and postoperative benign lesions sometimes overlap \[[@b13-usg-18028]\]. In patients who have undergone hysterectomy for a gynecologic malignancy, differentiating between recurrent disease and primary vaginal cancer may also be difficult radiologically \[[@b14-usg-18028]\]. PET/CT, as a problem-solving tool, also has some limitations in lesion characterization, leading to false positive or negative results \[[@b3-usg-18028],[@b15-usg-18028],[@b16-usg-18028]\], and it is expensive. For the patients with a radiologically indeterminate pelvic lesion, TRUS-or TVUS-guided biopsy may be useful to plan treatment strategies.

Uncertainty remains regarding the necessity of prophylactic antibiotics. Theoretically, the transrectal and transvaginal approaches are not completely aseptic. For prostate biopsy, antibiotic prophylaxis is well-established when the transrectal approach is used \[[@b17-usg-18028]\]. However, whether antibiotic prophylaxis is necessary for TVUS-guided biopsy remains controversial \[[@b4-usg-18028],[@b9-usg-18028]\]. Nevertheless, previous reports imply that transvaginal procedures may have a risk of infectious complications \[[@b18-usg-18028],[@b19-usg-18028]\]. Endovaginal flora or other pathogens may be transmitted into the pelvic cavity by a contaminated TVUS probe or biopsy needle \[[@b20-usg-18028]\]. For this reason, antibiotic prophylaxis was applied in this study for both TRUS- and TVUS-guided biopsies. More studies are necessary to determine the optimal preparations for biopsy.

This study has limitations. First, a single experienced operator performed the biopsies. The diagnostic performance of TRUS-and TVUS-guided biopsy should be tested in radiologists with various levels of experience with biopsy, which may provide useful information with respect to the learning curve and suggest the optimal threshold of experience. Second, a comparison between diagnostic and non-diagnostic biopsies was not made due to the limited statistical power, as only two patients had non-diagnostic results. Third, there was a risk of sampling error in the biopsies, because core biopsies might sample only the regions of peritumoral inflammation. Thus, clinical and imaging follow-up is necessary to reduce the likelihood of underestimation when the biopsy results for a lesion with a high suspicion of malignancy on imaging are non-diagnostic or suggestive of benignity.

In conclusion, this study externally validated the feasibility and safety of TRUS- or TVUS-guided biopsy. In addition, these techniques appear to enable accurate pathologic diagnoses of pelvic masses in oncologic patients to be made safely and relatively noninvasively.

No potential conflict of interest relevant to this article was reported.

![A 58-year-old woman who had a history of surgery for endometrial cancer.\
A, B. Axial T2-weighted (A) and fat saturation contrast-enhanced T1-weighted (B) images depict a solid mass, measuring 2.1 cm, in the vaginal vault (arrows). C. Transverse transvaginal ultrasound (TVUS) image also demonstrates a hypoechoic mass at the corresponding site (arrow). D. TVUS-guided core biopsy (arrows) with 4 cores reveals recurrent cancer.](usg-18028f1){#f1-usg-18028}

![A 63-year-old woman who had a history of surgery for sigmoid colon cancer.\
A. Contrast-enhanced computed tomography image depicts a solid mass (arrow), measuring 1.8 cm, abutting the anterior wall of the rectum (asterisk). B. Longitudinal transrectal ultrasound (TRUS) image also demonstrates a hypoechoic mass (arrow) at the anterior wall of the rectum (asterisk). C. TRUS-guided core biopsy (arrows) with three cores reveals recurrent cancer.](usg-18028f2){#f2-usg-18028}

![An 86-year-old woman who had a uterine mass.\
A. Contrast-enhanced computed tomography image depicts a cystic or necrotic mass (asterisk), measuring 10.5 cm, in the pelvic cavity. B. Longitudinal transvaginal ultrasound (TVUS) image also demonstrated a mass (asterisks) at the corresponding site of the uterus. C. TVUS-guided core biopsy with seven cores was performed in the echogenic portions of the mass (arrows), and it was nondiagnostic pathologically.](usg-18028f3){#f3-usg-18028}

###### 

Characteristics of the patients included in the study

  Parameter                                    Value
  -------------------------------------------- ----------------
  Patients characteristics                     
   Age (yr)                                    60.5 (23-89)
   Sex (male: female)                          12:28
   Proportion of oncologic patients, n (%)     20 (66.7)
  Radiologic characteristics                   
   Prebiopsy imaging, CT: MRI                  14:16
   Lesion size (cm)                            4.5 (0.9-13.0)
   Lesion nature (solid:cystic)                25:5
   Lesion location                             
    Perirectal space                           10
    Uterus or ovary                            7
    Vaginal vault                              5
    Pelvic sidewall                            5
    Bladder                                    3
  Biopsy characteristics                       
   Interval between imaging and biopsy (day)   8.5 (1-61)
   Approach type (TRUS:TVUS)                   19:11
   Biopsy core number                          4.0 (2-7)
   Biopsy distance (cm)                        2.4 (1.4-5.6)

Data of age, lesion size, interval between imaging and biopsy, biopsy core number, and biopsy distance are median (range).

CT, computed tomography; MRI, magnetic resonance imaging; TRUS, transrectal ultrasound; TVUS, transvaginal ultrasound.

###### 

Performance of TRUS- and TVUS-guided biopsy in diagnosing malignancy

  Parameter     Overall (n=28)   TRUS (n=18)   TVUS (n=10)
  ------------- ---------------- ------------- -------------
  Sensitivity   17/17 (100)      13/13 (100)   4/4 (100)
  Specificity   8/11 (72.7)      5/5 (100)     3/6 (50.0)
  PPV           17/20 (85.0)     13/13 (100)   4/7 (57.1)
  NPV           8/8 (100)        5/5 (100)     3/3 (100)
  Accuracy      25/28 (89.3)     18/18 (100)   7/10 (70.0)

Values are presented as number (%).

Of the 30 patients, two with non-diagnostic results were excluded from the analysis of diagnostic performance for malignancy because of the unclear information regarding malignancy or benignity.

TRUS, transrectal ultrasound; TVUS, transvaginal ultrasound; PPV, positive predictive value; NPV, negative predictive value.
